Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6977159

Title:Methods for inhibiting cutaneous inflammation and hyperpigmentation
Inventors:Longley, B. Jack; Hamden, CT, USA
Summary:This invention describes novel compounds for inhibiting the stem cell factor signaling pathway, methods and uses thereof. Further disclosed are constituents of the compounds as well as the means by which signaling pathways are inhibited. Therapeutic applications are included such as in the treatment of hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception. Claims of the invention include a specific suitability to the treatment and prevention of cutaneous inflammation and hyperpigmentation associated with such disorders as contact dermatitis, the successful treatment and prevention of which result from the effective inhibition of the specific stem cell signaling pathway addressed herein. Further described are the precise means of administration for delivering to a patient an antibody or portion thereof that binds to kit protein in an amount effective to inhibit the kinase enzymatic reaction of kit protein, which thereby inhibits the stem cell factor signaling pathway. This invention represents a continuation of other applications filed by the same assignee and inventor.
Abstract:This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6977159
Application Number:US2000000980572
Date Filed:05/05/2000
Date Published:20/12/2005
Assignee:The Trustees of Columbia University in the City of New York, New York, NY, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/4/2020